Talphera (TLPH) Revenue (2011 - 2025)

Talphera (TLPH) posted Revenue of $1000.0 for Q3 2025, down 96.3% on a QoQ basis from $27000.0 in Q1 2025.

Analysis

Talphera (TLPH) Revenue (2011 - 2025) Analysis & Trends

Talphera has reported Revenue for 14 years, with the latest figure at $1000.0 in Q3 2025.

On a quarterly basis, Revenue changed N/A year-over-year to $1000.0 in Q3 2025; TTM through Jun 2026 was $1000.0, a 96.3% decrease from a year earlier, with the FY2025 full-year figure at $28000.0, changed N/A from the prior year.
Revenue was $1000.0 for Q3 2025 at Talphera, down from $27000.0 in the prior quarter.
The five-year high for Revenue was $1.9 million in Q3 2021, with the low at $1000.0 in Q3 2025.
Average Revenue over 4 years is $403636.4, with a median of $281000.0 recorded in 2023.
The largest YoY upside for Revenue was 36.11% in 2021 against a maximum downside of 99.73% in 2021.
Over 4 years, Revenue stood at $2000.0 in 2021, then jumped by 22000.0% to $442000.0 in 2022, then sank by 36.43% to $281000.0 in 2023, then slumped by 99.64% to $1000.0 in 2025.
The last three Revenue figures came in at $1000.0 (Q3 2025), $27000.0 (Q1 2025), and $281000.0 (Q4 2023), per Business Quant data.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Amgen	206.71 Bn	192.72 Bn	7.24 Bn	10.05 Bn
2	Gilead Sciences	180.26 Bn	177.08 Bn	6.22 Bn	7.80 Bn
3	Vertex Pharmaceuticals	131.29 Bn	123.43 Bn	2.84 Bn	3.33 Bn
4	Regeneron Pharmaceuticals	81.82 Bn	73.83 Bn	3.93 Bn	4.29 Bn
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	1.52 Bn
6	Moderna	53.94 Bn	48.80 Bn	52.00 Mn	145.00 Mn
7	Alnylam Pharmaceuticals	33.34 Bn	30.03 Bn	992.69 Mn	1.29 Bn
8	Biogen	31.87 Bn	30.58 Bn	1.96 Bn	2.74 Bn
9	Roivant Sciences	29.02 Bn	29.02 Bn	1.16 Mn	1.44 Mn
10	Talphera	93.28 Mn	93.28 Mn	-	-

Historic Data

Download Data